TIDES: Oligonucleotide and Peptide Therapeutics is part of the Informa Connect Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.
Geoffrey Lynn, PhD, is co-founder and CEO of Avidea Technologies, a Baltimore-based biotechnology company that is developing polymer-based drug delivery platforms for immunotherapeutic applications. Avidea’s lead program is a personalized cancer vaccine (PCV) based on patient-specific peptide antigens linked to polymers that self-assemble into nanoparticles with precise, reproducible characteristics (e.g., particle size & peptide loading) irrespective of the underlying peptide antigen composition. Prior to joining Avidea, Geoffrey was a post-doctoral fellow with Robert Seder at the Vaccine Research Center at the National Institutes of Health. Geoffrey earned a B.S in chemistry from Elon University and a PhD (“D.Phil.”) in Biomedical Engineering from Oxford University in England.